Trial intelligence / Profile preview

RELAY-Brain

jRCT2051190027Phase 1Active, not recruiting

Sponsor: Eli Lilly and Company
Start: Sep 2019
Modality: Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 1, open-label trial of ramucirumab, erlotinib and osimertinib in non-small cell lung cancer (NSCLC) and brain metastases (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose-limiting toxicities. Started Sep 2019; status: active, not recruiting.

Drugs

ramucirumaberlotinibosimertinib

Conditions

non-small cell lung cancer (NSCLC)brain metastases

Beyond the preview

Go deeper on jRCT2051190027.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2051190027.